192 related articles for article (PubMed ID: 24522687)
1. Aldosterone antagonists in systolic heart failure.
Lindblad AJ; Allan GM
Can Fam Physician; 2014 Feb; 60(2):e104. PubMed ID: 24522687
[No Abstract] [Full Text] [Related]
2. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
Jacob MS; Tang WH
Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
[TBL] [Abstract][Full Text] [Related]
3. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
Dhillon S
Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669
[TBL] [Abstract][Full Text] [Related]
5. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F
Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: another drug to add to the mix?
Bart BA; Nelson S
J Am Coll Cardiol; 2013 Oct; 62(17):1594-5. PubMed ID: 23810879
[No Abstract] [Full Text] [Related]
9. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Verma A; Solomon SD
Curr Heart Fail Rep; 2007 Dec; 4(4):183-9. PubMed ID: 18221614
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
11. The clinical pharmacology of eplerenone.
Muldowney JA; Schoenhard JA; Benge CD
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):425-32. PubMed ID: 19379127
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
13. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
14. Cost effectiveness of eplerenone in patients with chronic heart failure.
Ademi Z; Pasupathi K; Krum H; Liew D
Am J Cardiovasc Drugs; 2014 Jun; 14(3):209-16. PubMed ID: 24610254
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Karagiannis A; Athyros VG; Mikhailidis DP
Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
[No Abstract] [Full Text] [Related]
18. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
[TBL] [Abstract][Full Text] [Related]
19. [Aldosterone antagonist therapy for chronic heart failure].
Yamamoto T; Yano M
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
[No Abstract] [Full Text] [Related]
20. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
